Header Logo

NAGESHWARA V. DASARI

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garc?a-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53. PMID: 37331369.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    2. Dasari A, Hamilton EP, Falchook GS, Wang JS, Li D, Sung MW, Chien C, Nanda S, Tucci C, Hahka-Kemppinen M, Paulson AS. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Invest New Drugs. 2023 Jun; 41(3):421-430. PMID: 37074571; PMCID: PMC10289989.
      Citations:    Fields:    Translation:Humans
    3. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S, Montagut C. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770. PMID: 32632268; PMCID: PMC7790747.
      Citations: 60     Fields:    Translation:Humans
    4. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1066-1075. PMID: 30610008; PMCID: PMC6693720.
      Citations: 4     Fields:    Translation:Humans
    5. Dasari A, Yao J. Initial treatment of well-differentiated neuroendocrine tumors. Oncology (Williston Park). 2014 Nov; 28(11):945-7. PMID: 25741544.
      Citations: 1     Fields:    Translation:Humans
    6. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park). 2014 Sep; 28(9):762-3. PMID: 25224473.
      Citations:    Fields:    Translation:HumansAnimals
    7. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71. PMID: 25069797; PMCID: PMC4266576.
      Citations: 48     Fields:    Translation:Humans
    8. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014 Aug; 32(4):739-45. PMID: 24668033; PMCID: PMC4292847.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    9. Rogers JE, Ohinata A, Dasari A, Eng C. Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer. 2014 Mar; 13(1):e1-4. PMID: 24342822.
      Citations: 3     Fields:    Translation:Humans
    10. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr; 31(2):345-54. PMID: 22615057; PMCID: PMC3674958.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    11. Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res. 2012 May 01; 18(9):2704-14. PMID: 22553375; PMCID: PMC3836589.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    12. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2348-53. PMID: 22529266; PMCID: PMC5950496.
      Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
    13. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a ?-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol. 2012 Jun; 6(3):370-81. PMID: 22521243; PMCID: PMC4033713.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    14. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25. PMID: 22415798.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    15. Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol. 2012 Feb; 19(1):e36-41. PMID: 22328846; PMCID: PMC3267595.
      Citations: 10     Fields:    
    16. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park). 2010 Dec; 24(14):1329-34. PMID: 21294478.
      Citations: 1     Fields:    Translation:Humans
    17. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010 Aug 01; 16(15):3811-8. PMID: 20554751.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    18. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 2006 Nov 15; 66(22):10805-14. PMID: 17108117; PMCID: PMC4288740.
      Citations: 96     Fields:    Translation:HumansAnimalsCells
    19. Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22:431-441.
    20. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26:731-736.
    21. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. Journal of Gastrointestinal Surgery. 20:1966-1974.
    22. Initial treatment of well-differentiated neuroendocrine tumors. ONCOLOGY (United States). 28.
    23. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery (United States).
    24. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology. 24.
    25. γ-secretase inhibitors in solid tumor malignancies. Drugs of the Future. 36:677-689.
    26. Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. Oncologist. 21:308-313.
    27. The treatment of colorectal cancer during pregnancy. Oncologist. 21:563-570.
    28. Gastrointestinal neuroendocrine tumors. ONCOLOGY (United States). 28.
    29. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncology. 12:313-321.
    30. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery. 1-9.
    31. High-Grade Neuroendocrine Colorectal Carcinomas. Clinical Colorectal Cancer.
    32. Should we perform a new adjuvant trial with bevacizumab?. Current Colorectal Cancer Reports. 7:218-226.
    33. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.
    34. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 45:783-785.
    35. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. Journal of Clinical Oncology. 33:4032-4038.
    DASARI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (130)
    Explore
    _
    Co-Authors (15)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _